Welcome to our dedicated page for Clearmind Medici news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medici stock.
Clearmind Medicine Inc. develops clinical-stage neuroplastogen-derived therapeutics focused on mental health and substance-use disorders. News for CMND centers on CMND-100, the company's proprietary non-hallucinogenic MEAI-based oral drug candidate for Alcohol Use Disorder, including clinical-trial safety, tolerability, pharmacokinetic and preliminary efficacy updates from a multinational Phase I/IIa study.
Company updates also cover intellectual-property activity for psychedelic and neuroplastogen compounds, including patent applications and licensed development rights tied to PTSD and other mental health disorders. Additional recurring themes include FDA-related clinical communications, data-safety monitoring reviews, clinical-site progress and scientific presentations around MEAI.
Clearmind Medicine Inc. (Nasdaq: CMND) has announced the publication of an international patent application for a pioneering combination therapy of Ibogaine and N-Acylethanolamines. This innovative treatment, developed in collaboration with SciSparc (Nasdaq: SPRC), aims to enhance safety and efficacy in mental health and addiction care.
Ibogaine, derived from the Tabernanthe iboga shrub, has shown promise in treating various substance use disorders. The combination with N-Acylethanolamines, including Palmitoylethanolamide (PEA), is expected to further improve the therapy's effectiveness and safety profile. This development underscores Clearmind's commitment to leadership in the psychedelics space and its focus on providing safe solutions for unmet mental health needs.
Clearmind Medicine Inc. (Nasdaq: CMND) has filed an international patent application for innovative psychedelic compounds designed to treat post-traumatic stress disorder (PTSD) and other mental health conditions. This application is part of Clearmind's collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem. The compounds were invented by Professors Rami Yaka, Ahmed Masaewa, and Avi Priel.
The global PTSD treatment market, valued at $16.8 billion in 2023, is projected to reach $27.37 billion by 2033. Current PTSD treatments offer efficacy, and FDA-approved drugs often come with side effects. Clearmind aims to develop effective and safe next-generation psychedelic compounds to significantly improve patients' quality of life.
Clearmind Medicine Inc. (Nasdaq: CMND) has announced the publication of an international patent application for a novel combination treatment using MDMA and N-Acylethanolamines. This innovative approach aims to enhance safety and efficacy in mental health and addiction treatments. The patent is part of Clearmind's collaboration with SciSparc (Nasdaq: SPRC), focusing on integrating psychedelic molecules with N-Acylethanolamines, including Palmitoylethanolamide (PEA).
Dr. Adi Zuloff-Shani, CEO of Clearmind, emphasized that this combination therapy addresses FDA safety concerns about MDMA by potentially reducing its dosage while maintaining therapeutic efficacy. The company has filed thirteen patents related to this collaboration in various global jurisdictions, demonstrating their commitment to developing innovative treatments for mental health disorders and addictions.
Clearmind Medicine Inc. (Nasdaq: CMND) has announced the publication of its patent application for innovative combinations of Ketamine and N-Acylethanolamines. This is a result of their ongoing collaboration with SciSparc (Nasdaq: SPRC). The companies are researching combination therapies integrating SciSparc's Palmitoylethanolamide (PEA) with Clearmind's psychedelic molecule MEAI, targeting addictions, weight loss, and mental health disorders.
To date, thirteen patents related to this collaboration have been filed globally. The goal is to develop treatments that maintain effectiveness while reducing doses and minimizing side effects. This approach could potentially address concerns associated with FDA-approved ketamine treatments, which require strict usage guidelines and close supervision due to potential side effects and abuse risks.
Clearmind Medicine Inc. (Nasdaq: CMND) has received a new patent approval from the United States Patent and Trademark Office for its MEAI-based binge behavior regulator program. The patent covers methods of regulating alcoholic beverage consumption and controlling binge behavior through the administration of amine aminoindane, including 5-methoxy-2-aminoindan (MEAI), the company's innovative psychedelic molecule.
This approval strengthens Clearmind's intellectual property portfolio, which now includes 29 granted patents across 19 patent families in key jurisdictions such as the U.S., Europe, China, and India. MEAI is a novel psychoactive molecule that reduces the desire to consume alcohol while providing a mild euphoric, alcohol-like experience. Clearmind's MEAI-based flagship treatment targets Alcohol Use Disorder (AUD) and weight loss, with potential applications in treating binge drinking.
Clearmind Medicine Inc. (Nasdaq: CMND) has announced the submission of an international patent application for generation 3.0 psychedelic compounds to treat mental disorders. This application is part of the company's ongoing collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem. The patent, developed by Prof. Dmitry Tsvelikhovsky, covers new psychedelic compounds, their preparation methods, and therapeutic uses.
The PCT submission allows Clearmind to proceed with national phase applications in major jurisdictions like the US, Europe, China, and India. Dr. Adi Zuloff-Shani, CEO of Clearmind, emphasized the potential of these advanced molecules to offer improved therapeutic options for patients with mental disorders. Clearmind, a clinical-stage psychedelic pharmaceutical biotech company, focuses on developing novel psychedelic-derived therapeutics for underserved health problems, including alcohol use disorder.
Clearmind Medicine Inc. (Nasdaq: CMND) announced promising results from a study on 5-methoxy-2-aminoindane (MEAI) for combating obesity. The research, led by Prof. Joseph Tam at the Hebrew University of Jerusalem, revealed significant findings:
1. Weight loss: MEAI reduced diet-induced obesity in mice, decreasing fat mass while preserving lean mass.
2. Improved metabolism: MEAI enhanced glycemic control by reducing hyperglycemia, glucose intolerance, and hyperinsulinemia.
3. Fatty liver disease: MEAI decreased fatty liver by lowering liver triglyceride and cholesterol levels.
4. Increased energy expenditure: MEAI boosted energy expenditure and fat utilization without affecting food consumption.
5. Activity: MEAI increased activity-specific energy expenditure without overstimulation.
Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, highlighted MEAI's potential as a breakthrough in obesity treatment, citing its efficacy, unique mechanism of action, and easy administration without food consumption constraints.
Clearmind Medicine Inc. (Nasdaq: CMND) successfully participated in the Psychedelic Medicine – Israel 2024 conference in Tel Aviv. CEO Adi Zuloff-Shani presented on '5-Methoxy-2-Aminoindane (MEAI) as a Binge Behavior Regulator', highlighting its potential in treating addiction-related disorders. Researchers from The Hebrew University of Jerusalem also presented an abstract on MEAI's ability to attenuate diet-induced obesity and related metabolic complications.
The conference provided Clearmind an opportunity to showcase its innovative therapies, engage with industry leaders, and expand its network of partners. Dr. Zuloff-Shani noted that the MEAI research garnered significant interest and acceptance among event participants, reinforcing Clearmind's position in the psychedelic-derived therapeutics field.
Clearmind Medicine Inc. (Nasdaq: CMND) has partnered with JS First Sdn. Bhd to source global manufacturers and distributors for its MEAI-based alcohol substitute beverages. This strategic move follows Clearmind's recent entry into the non-alcoholic beverage market with its patented, neurologically active novel alcohol replacement drink. The beverage aims to offer the social benefits of alcohol without negative health impacts.
JS First will conduct research on manufacturing and licensing rights in foreign markets, identify manufacturing partners, and establish relationships with distributors globally. The collaboration targets markets in the U.S., Europe, Africa, and Southeast Asia. According to IWSR, the no- and low-alcohol market is valued at over $13 billion and is forecast to grow at a CAGR of +6% between 2023 and 2027.
Clearmind Medicine Inc. (Nasdaq: CMND) has received FDA approval for its Investigational New Drug (IND) application, allowing the company to proceed with a Phase I/IIa clinical trial in the United States for its proprietary MEAI-based CMND-100 oral capsule to treat alcohol use disorder (AUD). The multinational, multi-center trial will assess tolerability, safety, and pharmacokinetics in healthy volunteers and AUD subjects.
The trial will be conducted at leading universities in the US, including Yale and Johns Hopkins, as well as in Israel. The primary endpoint is to determine the tolerable dose and characterize safety and pharmacokinetics, while the secondary endpoint will evaluate preliminary efficacy in reducing drinking patterns and cravings in moderate-to-severe AUD patients.